

An unresolved and still open issue in the recent AHA scientific statement on Fontan circulation

Short title: a neglected issue

BASSAREO Pier Paolo¹, CALCATERRA Giuseppe², GARGIULO Gaetano Domenico³

- 1 University College of Dublin, Mater Misericordiae University Hospital, National Adult Congenital Heart Disease Service, Dublin, Republic of Ireland*
- 2 Pediatric cardiologist Post Graduate Medical School of Cardiology, University of Palermo, Palermo, Italy*
- 3 Pediatric and Grown-up Congenital Cardiac Surgery Unit, Director, University of Bologna, Bologna, Italy*

Corresponding author:

*Pier Paolo Bassareo MD, PhD, MSc, Scholar in Cardiologia, FESC
University College of Dublin
Mater Misericordiae University Hospital
Eccles St, Inns Quay, Dublin 7, D07 R2WY
Dublin, Republic of Ireland
Telephone: +35314096083
Mail: piercard@inwind.it*

Keywords: infective endocarditis, antibiotic prophylaxis, Fontan procedure, Guidelines

We really appreciated the masterful, comprehensive review released by the AHA for the 50th anniversary of the surgical intervention introduced by Fontan [1]. Though dealing with nearly all elements related with this so particular setting, at least an important point seems not to be enough highlighted, namely the potential risk of infective endocarditis (IE) and the indication for antibiotic prophylaxis (AP).

Since 2007, the AHA Guidelines on IE suggested that AP is reasonable for the subset of “high risk” population [2] such as patients with complex congenital heart disease, namely:

- *unrepaired cyanotic defects, including palliative shunts and conduits*
- *completely repaired defects with prosthetic material or device, whether placed by surgery or catheter intervention (during the first 6 months after the procedure)*
- *repaired defects with residual shunts at the site or adjacent to the site of a prosthetic patch or prosthetic device*

In this respect, the majority of Fontan patients seem to belong to the “high risk” category, as they have a cyanotic complex congenital heart disease and because of the presence of homograft valved conduit in some “classic” Fontan procedures (nowadays abandoned for early calcification and pathways obstruction), use of prosthetic material for the intra-atrial tunnel or extracardiac conduit, presence of residual shunt in case of fenestrated total cavo-pulmonary connection and use of devices to close the fenestrated Fontan conduits, coils to embolize veno-venous collaterals, stents for stenotic pulmonary branches. Finally, we should consider -in a philosophical way- that this procedure is palliative and not a definitive repair for anatomical or functional univentricular heart.

Furthermore, the 2015 AHA Update on IE in childhood outlined that “the disproportionately large focus on AP” should be replaced by “oral hygiene and prevention of oral disease”, thus implicitly accepting the paradigm introduced in 2007 for adults. No specific mention of Fontan patients was made at all [3].

Such an important and comprehensive review should answer a still open question: Is Fontan population likely to develop IE? Is AP needed to prevent IE in this setting?

There is no doubt that IE occurrence in Fontan patients is extremely rare, with very few anecdotal literature reports, thus confirming our personal experience. It implies two things markedly contrasting each other: 1) AP is always efficient in the Fontan setting,

which to put it bluntly is unlikely *or* 2) Fontan patients are not at “high risk” for IE. Regarding the latter, in the so called “IE triangle”, a new approach capable of explaining the complex interplay leading from an uncomplicated bacteremia to IE, the apex of the triangle (favourable anatomical substrate) should include also a turbulent blood flow to make bacterial adhesion easier [4]. Conversely, in the Fontan circuit the hematic flow is very slow, owing to the lack of a “pumping” sub-pulmonary ventricle. The post-capillary energy of systemic circulation drives the flow through pulmonary capillaries without any turbulence. It may explain why Fontan individuals are so resistant to IE.

Overall, we are still wondering whether Fontan patients should undergo AP to prevent IE during dental procedures.

References

1. Rychik J, Atz AM, Celermajer DS, Deal BJ, Gatzoulis MA, Gewillig MH, Hsia TY, Hsu DT, Kovacs AH, McCrindle BW, Newburger JW, Pike NA, Rodefeld M, Rosenthal DN, Schumacher KR, Marino BS, Stout K, Veldtman G, Younoszai AK, d'Udekem Y; American Heart Association Council on Cardiovascular Disease in the Young and Council on Cardiovascular and Stroke Nursing. Evaluation and Management of the Child and Adult With Fontan Circulation: A Scientific Statement From the American Heart Association. *Circulation* 2019, in press. Doi: 10.1161/CIR.0000000000000696
2. Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, Bolger A, Cabell CH, Takahashi M, Baltimore RS, Newburger JW, Strom BL, Tani LY, Gerber M, Bonow RO, Pallasch T, Shulman ST, Rowley AH, Burns JC, Ferrieri P, Gardner T, Goff D, Durack DT; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Surgery and Anesthesia; Quality of Care and Outcomes Research Interdisciplinary Working Group. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and

Outcomes Research Interdisciplinary Working Group. *Circulation* 2007;116:1736-1754.

3. Baltimore RS, Gewitz M, Baddour LM, Beerman LB, Jackson MA, Lockhart PB, Pahl E, Schutze GE, Shulman ST, Willoughby R Jr; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association. *Circulation* 2015;132:1487-1515.
4. Calcaterra G, Crisafulli A, Guccione P, Di Salvo G, Bassareo PP. Infective endocarditis triangle. Is it the time to revisit infective endocarditis susceptibility, and indications for its antibiotic prophylaxis? *Eur J Prev Cardiol* 2019, in press. doi: 10.1177/2047487319856126.

Response to letter from Bassareo, Calcaterra and Gargiuolo: “An unresolved and still open issue in the recent AHA scientific statement on Fontan circulation.

Jack Rychik, MD, David S. Celermajer, MBBS, PhD, Yves d’Udekem, MD, PhD

Correspondence to:

Jack Rychik, MD

Cardiac Center at The Children’s Hospital of Philadelphia

Philadelphia, PA USA 19104

Phone: 215.590.2192

Email: Rychik@email.chop.edu

Letter Response:

Although intended to be as comprehensive as possible, we acknowledge the gap in our recent AHA scientific statement on Fontan circulation (1), as regards infective endocarditis (IE) prophylaxis, as raised by Bassareo et al. There is little published information on the risk of IE in patients living with a Fontan circulation. Two recently published series are potentially informative. Among adults with congenital heart disease (CHD) who have developed sub-acute bacterial endocarditis (79 cases in 85,000 patient years), no cases were reported in Fontan patients (2) and in adults with Fontan circulation followed for over 30,000 patient years, no cases of IE were reported (3).

IE in the patient with a Fontan circulation appears to be a very unusual and rare event. Nevertheless, the current AHA recommendations concerning SBE prophylaxis identify individuals at high-risk with concepts that may apply (4,5). The following patient groups with CHD are associated with the highest risk of adverse outcome from endocarditis and thus prophylaxis is reasonable: 1) unrepaired cyanotic CHD including palliative shunts and conduits, 2) completely repaired CHD with prosthetic material or device, placed by surgery or catheter, during first 6 months after procedure, or 3) repaired CHD with residual defects at the site of a prosthetic patch or prosthetic device (which inhibits endothelialization).

One could readily see how an individual with a Fontan circulation might fall into one or more of these categories, yet we acknowledge the challenge of a perfect fit into this construct. A number of valid questions can be raised. For example, are those with a Fontan circulation and mild cyanosis “repaired” or “un-repaired”? The extra-cardiac conduit and lateral tunnel-type Fontan surgeries include prosthetic material, but these exist within a venous, low flow state. Is there increased risk of bacterial adhesion in such conditions? Is a fenestration a “residual defect” and does it increase risk?

For the moment decisions on IE prophylaxis may need to be left to the judgment of healthcare providers as applied to individual patients within the context of the current AHA guidelines. As with many aspects of care and management for the patient with Fontan circulation, gaps in knowledge exist and the ideal strategies to optimize long-term health and wellness are still emerging. The role of IE prophylaxis will require

further investigation before definitive evidence based recommendations specific to this population can be made.

REFERENCES

1. Rychik J, Atz AM, Celermajer DS, Deal BJ, Gatzoulis MA, Gewillig MH, Hsia TY, Hsu DT, Kovacs AH, McCrindle BW, Newburger JW, Pike NA, Rodefeld M, Rosenthal DN, Schumacher KR, Marino BS, Stout K, Veldtman G, Younoszai AK, d'Udekem Y; American Heart Association Council on Cardiovascular Disease in the Young and Council on Cardiovascular and Stroke Nursing. Evaluation and Management of the Child and Adult With Fontan Circulation: A Scientific Statement From the American Heart Association. *Circulation*. 2019 Jul 1;CIR0000000000000696. doi: 10.1161/ [Epub ahead of print]
2. Moore B, Yu C, Kotchetkova I, Cordina R, Celermajer DS. Incidence, predictors and outcomes of infective endocarditis in a contemporary adult congenital heart disease population. *Int J Cardiol*. 2017 Dec 15;249:161-165.
3. Dennis M, Zannino D, du Plessis K, Bullock A, Disney PJS, Radford DJ, Hornung T, Grigg L, Cordina R, d'Udekem Y, Celermajer DS. Clinical Outcomes in Adolescents and Adults After the Fontan Procedure. *J Am Coll Cardiol*. 2018 Mar 6;71(9):1009-1017.

4. Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, Bolger A, Cabell CH, Takahashi M, Baltimore RS, Newburger JW, Strom BL, Tani LY, Gerber M, Bonow RO, Pallasch T, Shulman ST, Rowley AH, Burns JC, Ferrieri P, Gardner T, Goff D, Durack DT; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Cardiovascular Surgery and Anesthesia; Quality of Care and Outcomes Research Interdisciplinary Working Group. [Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group.](#) Circulation. 2007 Oct 9;116(15):1736-54.

5. Baltimore RS, Gewitz M, Baddour LM, Beerman LB, Jackson MA, Lockhart PB, Pahl E, Schutze GE, Shulman ST, Willoughby R Jr; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. [Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association.](#) Circulation. 2015 Oct 13;132(15):1487-515.